{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:49:24Z","timestamp":1781650164080,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T00:00:00Z","timestamp":1503273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/nrneph.2017.118","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T04:59:08Z","timestamp":1503291548000},"page":"600-602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["KDIGO CKD\u2013MBD guideline update: evolution in the face of uncertainty"],"prefix":"10.1038","volume":"13","author":[{"given":"Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Bushinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"key":"BFnrneph2017118_CR1","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 7, 1\u201359 (2017)."},{"key":"BFnrneph2017118_CR2","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 113, S1\u2013S130 (2009)."},{"key":"BFnrneph2017118_CR3","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.2215\/CJN.05970809","volume":"5","author":"DA Bushinsky","year":"2010","unstructured":"Bushinsky, D. A. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. Clin. J. Am. Soc. Nephrol. 5, S12\u2013S22 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2017118_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/ki.2011.490","volume":"81","author":"DM Spiegel","year":"2012","unstructured":"Spiegel, D. M. & Brady, K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int. 81, 1116\u20131122 (2012).","journal-title":"Kidney Int."},{"key":"BFnrneph2017118_CR5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ki.2012.403","volume":"83","author":"KM Hill","year":"2013","unstructured":"Hill, K. M.  et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3\u20134 chronic kidney disease. Kidney Int. 83, 959\u2013966 (2013).","journal-title":"Kidney Int."},{"key":"BFnrneph2017118_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AY Wang","year":"2014","unstructured":"Wang, A. Y.  et al. Effect of paricalcitol on left ventricular mass and function in CKD\u2014the OPERA trial. J. Am. Soc. Nephrol. 25, 175\u2013186 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2017118_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani, R.  et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307, 674\u2013684 (2012).","journal-title":"JAMA"},{"key":"BFnrneph2017118_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2215\/CJN.06040614","volume":"10","author":"KL Naylor","year":"2015","unstructured":"Naylor, K. L.  et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin. J. Am. Soc. Nephrol. 10, 646\u2013653 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2017118_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jbmr.2406","volume":"30","author":"SL West","year":"2015","unstructured":"West, S. L.  et al. Bone mineral density predicts fractures in chronic kidney disease. J. Bone Miner. Res. 30, 913\u2013919 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2017118_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","volume":"56","author":"ND Toussaint","year":"2010","unstructured":"Toussaint, N. D., Lau, K. K., Strauss, B. J., Polkinghorne, K. R. & Kerr, P. G. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am. J. Kidney Dis. 56, 57\u201368 (2010).","journal-title":"Am. J. Kidney Dis."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2017.118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2017.118","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrneph.2017.118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2017.118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:49:40Z","timestamp":1684471780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2017.118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,21]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFnrneph2017118"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2017.118","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,21]]},"assertion":[{"value":"21 August 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.B. is a consultant for Relyspa, Amgen, Sanofi\/Genzyme, Vifor, and Tricida and has an equity interest in Amgen and Tricida. W.C. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}